đ° Markm Davis News
Page 2 - Markm Davis News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Markm Davis. Real-time updates on events, politics, business and more.
October 7, 2022
The artificial intelligence model could be utilized to enable more effective care for skin cancer patients and could lead to similar breakthroughs in the diagnosis and treatment of other cancers.
August 25, 2022
Immunotherapy company developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases in broad...
July 14, 2022
Milwaukee, WI (PRWEB) July 14, 2022 -- The Society for Immunotherapy of Cancer (SITC) announces the 2022 class of Fellows of the Academy of Immuno-Oncology
October 27, 2021
Mozart Therapeutics Launches with $55 Million Series A Financing to Develop Disease Modifying Therapeutics for Autoimmune and Inflammatory Diseases - read this article along with other careers information, tips and advice on BioSpace
October 22, 2021
A molecular machine is “an assemblage of parts that transmit forces, motion, or energy from one to another in a predetermined manner.
February 18, 2021
Share this article Share this article ROCKVILLE, Md., Feb. 18, 2021 /PRNewswire/ -- The National Foundation for Cancer Research (NFCR) announced today that the 2021 Szent-Györgyi Prize for Progress in Cancer Research will be awarded to Tak W. Mak, Ph.D., senior scientist at the Princess Margaret Cancer Centre and university professor at the University of Toronto, and Mark M. Davis, Ph.D., professor of microbiology and immunology at the Stanford University School of Medicine, for their break...
February 3, 2021
Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data and Publication January 26, 2021 08:30 ET | Source: Vaxart, Inc. Vaxart, Inc. South San Francisco, California, UNITED STATES New pre-clinical histology data show that Vaxartâs oral vaccine protected against lung inflammation in hamster models An article published in Nature Medicine reports data from a collaboration with Stanford University researchers on in vitro activity of Vaxartïżœ...
January 26, 2021
Published: Jan 26, 2021 New pre-clinical histology data show that Vaxartâs oral vaccine protected against lung inflammation in hamster models An article published in Nature Medicine reports data from a collaboration with Stanford University researchers on in vitro activity of Vaxartâs COVID-19 vaccine Data from Vaxartâs Phase I COVID-19 trial expected to be released next week SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Vaxart Inc., (NASDAQ: VXRT), a clinical-stage ...